michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. I think there's two kind of key things here. One is we're definitely -- and especially in the March and into April, for sure, have seen the impact of industrial recovery impact the LTL business. As you know, our client base on the LTL side is much more small and midsized companies versus very large shippers, and so they were probably disproportionately impacted during the early phases of the pandemic. And starting to see some of that recovery as well as hitting favorable comps in April. The second big driver has been the success we have in the managed transportation business. So that's driven a pretty significant amount of growth in LTL. The only kind of interesting setback, if you will, was the freeze event in Q1. So that created really some big service challenges on the LTL side and lots of delayed deliveries. So we did have a kind of like a dip in volume growth in February. But again, like I said earlier, accelerated in March, accelerated even further in April. So we've always been a strong LTL, SMB market provider. We feel really great about EchoShip, our ability to handle customers online, pursue micro shippers, SMB shippers in a multimodal way. And I think that's a big reason that we're having continued success on the LTL side.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, definitely, I can take it as well. Look, for product inspection, I think for us pretty much it will be that the investment in the end market comes back and the confidence in the end market comes back and that customers will be willing, again, to invest in their facilities to bring people into their facilities. They have been pretty restrictive given the COVID-19 situation. As I said, I think in my introductory remarks, the product line has been facing issues even with bringing service people into some of the customer sites because they were so afraid of the COVID-19 situation there. So as that market as the COVID-19 situation eases up, we think that some of the pent-up demand of our customers will then materialize for us also into somewhat higher growth rates toward the second half of the year.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi, thank you. I've got a couple of questions. Just one on the retail side, Donnie, you said that pricing is having trouble keeping up with the inflation, but you do have an increase coming in September. To what extent does that fully offset all the inflation you've seen? Of course, you need another price increase right after that because it's an upward sloping curve.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes hi. So the first thing I want to understand a little bit is as you think about your contracts and your pass-through mechanisms and recovery, how do they differ by region, EMEA, South American and North Central America? And how should we think about the price cost performance in the next few quarters by each region?

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. So the traction market for Powell, so a couple of years ago, I made a couple of comments on the call about some approach the market being disciplined. This is a market that, as you know, the money flows out of a lot of government entity by local or have federal matching funds. And then there's a lot of contracting layers unlike some of our industrial business. So there is -- in my words, a little bit more risk by the time the project gets to Powell because we're several layers down in the contracting piece. So that isn't fundamentally changing. But we are good at what we do.
The growth over the last couple of years has been more of the penetration into Canada. Whereas if I look at the US domestic business, it's been solid and hasn't sort of maintained, but we've applied this discipline to how we're going to approach the market, and then taking that know-how and discipline into Canada. So that's where we've seen some of the growth last couple of years at the revenue line. And with the Infrastructure Bill, absolutely watching it closely, how will that -- again, especially those matching funds, will they start to move some of these projects forward. There's still some remedial work going on across different agencies. Will just start to move projects forward and put Powell in a position to capitalize more. I guess, I'm still a little hopeful there versus being solidly confident that it's going to move the needle, but we are going to do what we can to capitalize on those projects that make sense for Powell where we align well with the contractors that are selected for those agency jobs.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, I am not going to answer a question that specific to a customer. However, I will say, I'm looking at the hot off the press earnings results from our -- the Hyperscale Cloud providers looking at their capex rates and feeling very good about that because as long as their business is performing well, they will need to invest in their infrastructure to maintain that strength, to keep up with the demand that they're seeing and we will benefit from that.
The simplest that our footprint in routing within Hyperscale is phenomenal. We've maintained that footprint despite many attempts by competitors to take slices of it away from us. And then as you get into the top 10 and Cloud major, it's not just about routing, it's about routing and switching for us.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure, sure. It's, as you know there is some disruption from other merger activity in both markets, we're benefiting from that through the attraction of people as well as customers. We are actively on boarding those customers we assisted with PPP. We are building loan pipeline and loan portfolio and deposit from that. We have, what we instituted years back, was a very focused customer solicitation program identifying what a core customer is at Valley's, identifying programs and processes to on-board them, cross-selling them and then rewarding our people based on their performance. That's not new, that we've been doing that, that has reaped benefits for us and created a consistency. The Northeast has been very steady growth for us though we're getting faster growth in the Southeast. The competitive landscape is active, it's there, it's not just banks, but we are getting our fair share.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good morning. Thanks for taking my questions. A very quick one on mortgages. Conscious, we've beaten it to death, almost.
Am I right to think that, that 145 basis points of -- I think you said at the end of the quarter, is that still above the rates of which the business that's rolling over? I realize you mentioned the back book, but versus the fixed-rate business rolling over is still above. And when we think about the next few quarters, given the volumes and given it's rolling over above, any reason why we shouldn't see sort of NII sort of growing, obviously, for the adjustment of the one-off that is -- put another way, is the commercial sort of banking drag something we should take into account? And then -- and maybe one more medium-term one. I think you said to Jonathan's question that you have 75 basis points rate hike expectations over the next three years. I'm trying to remember what you had in your 9% to 10% guidance at the beginning of the year for 2023.
And given the margin expectation, it just makes me think that there's upside to that 9% to 10%. Obviously, rate hikes have to happen and all that, but I just wanted to compare versus your earlier guidance in the strategy plan at the beginning of the year.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. Cory, let me start with telling you a little bit more about the regulatory process and something a little bit more on manufacturing, which is your specific question. And then Ill ask Stuart to comment on Europe. Obviously, we are -- we have the opportunity not only in Europe but the opportunities certainly including Europe to lead from the front with our CTX001 for both beta thalassemia and sickle cell disease. Okay. So Cory, on the regulatory filings, because of these designations weve had a benefit of multiple conversations with the agency and as I said earlier, been able to address most of their questions, and were really now wrapping up conversations around two clinical points, which is how big is the database and whats the duration of follow-up.
On the manufacturing side, we are using the same processes and actually the same sites as we did for the clinical trials for the commercial product. And in the grand scheme of things, when you think about what we are doing with CTX001, its ex vivo gene editing. And really, its the Cas enzyme and the guide RNA. And in the grand scheme of things, thats just simply an easier manufacturing situation than other manufacturing challenges. So I feel very good about our conversations with the agency. Weve been able to derisk by addressing their questions along the way. And we are using the same processes and the same sites that we used in the clinical trials for the commercial product. Stuart, a couple of comments maybe from you about Europe and CTX001.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hey, guys. It's Chris on for Greg, how are you?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. So the margin in backlog is -- well, let me answer it a little differently, and I'll come back to that. The expectation of margins as we go into the back half is fairly substantial increase in Q3 and Q4, and it's driven by the things that we've been talking about. There's, of course, price.
But as you said, that's not the biggest part. Operating leverage is fairly a big component of this. We took out a lot of costs last year, and we've continued to do that into this year. So we should see good drop-through in the 30% to 35% range as we enter Q3 and then go again into Q4.
Those are two big ones. We're seeing some favorable mix, as well as in the backlog aftermarket. In short cycle, some of our more profitable end markets are leading the recovery. So we should have some favorable mix as we go into the back half.
So there's nothing special about the margin in backlog. I think it's mostly around the things that we've done from an execution standpoint as we go into Q3 and Q4 that are going to drive the bottom line.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, on SFR loans, I would say both channels are open. We actually did sell a block of SFR loans last year, which would have securitized a little bit less efficiently than some of the core SFR loans that we're currently producing. So both channels are open. We certainly have been securitizing the preponderance of what we have been originating in SFR, but clearly, if executions move, there's very robust whole loan demand for these. But as you know, the ability to keep the subordinate pieces and deploy capital there is.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi, everyone. This is Nick Rubino on for Annabel. Thanks for taking our questions. A few from us. First,are you guys currently engaging with physicians in kind of this I guess soft launch that you're currently in? And then, how are things going to change once you have the product in hand? I know you mentioned kind of sampling programs as being a large part of that. And kind of how are you integrating that with physicians and how should we see physicians kind of utilizing that program? Then second, on pricing, you guys are at kind of the low end of the range of options, how is that facilitating payer conversations? And lastly, can you just remind us quickly about viloxazine IP in the US? We know it's an NCE but kind of what's the broad patent portfolio strength like? Thank you.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. Thanks Bob. It's a great question. As we announced -- when we had that announced quarter the deal we signed with Genesis is really a multifaceted deal that -- around five of our Neuro products. And we think it has a great potential for us over the next number of years. But we also -- as I said in the prepared remarks today, it's the beginning. It's -- we think there's more we can do even than that in China. So yes, we had another good quarter with China. And we think going forward we will continue to see that playing an important role for us. And we're excited about it to bring this technology first with these products in neuro and then across our larger portfolio to that country.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So when we met with the Board in January, and we highlighted some of the opportunities for the business, Rosemarie. One of the opportunities is really to strengthen our product portfolio in North America. And really, we're prioritizing the SBM business because of the outlook for residential construction and also because of the significant margins that we earn in that business. So actually, we have been very active looking at the landscape, and we have two active targets we're considering, and I think it would be a great achievement for the business if we could close on one of those in 2021.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. So thanks for the question on Tukysa. As you know, Tukysa is approved for patients with visual disease, as well as patients with -- with brain mets. And we are certainly using it in both patients and getting a lot of uptake there.
Chip, could you comment a little bit on the dynamics in the market of using Tukysa in -- in brain mets and in patients with visual disease?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good morning, guys. So wanted to follow-up on the shift toward store expansion. Basically, Tom, why do you think now is the time to shift toward expansion from your prior consolidation efforts?

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, no, listen. Kevin, thanks for the question. I'll let -- I'm going to ask John in a second to refer to the dollar rate the -- the math I guess behind that and the -- and the underlying trends. As far as sequestrations are concerned, obviously, we, you know, we're keeping a close eye on the guidance from the administration.
We -- you know, we've clearly seen the extensions. But the guidance range we've given today is not caveated by that in any way. So, you know, we -- we -- we have our assumptions on that, but the guidance stands notwithstanding any outcome there. John, on the $1.80.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So we're not really -- it's early days and we're not in a position to give guidance. But as Arnold said, the pricing environment is very strong. Our brands have done a lot to raise price over time. There's a lot of pent-up demand out there and we feel very good about our overall position. Booking volumes, as we said, have been increasing and so all these signs point in the right direction. But I do think it's premature for me to give guidance at this point.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
This is what Andrey said, I'm sorry.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, the way to make sure that happens is we get customers to make commitments to buy capacity before you install it. And historically, we haven't done that, but over the last four or five years, we had. So we actually make it more difficult for ourselves to buy capital because we have to do a lot of work in advance of it. But the impact on the financial company, I think shows now clearly for itself. So yes, it's a good time to be adding capacity in our markets. Having said that, in the IC product business at the high end, qualifying new capacity, and new nodes takes time. So you can install a tool and it could easily be six or nine months until it's fully utilized, not because demand isn't present, but because the customers require extensive qualification to ensure that it doesn't affect their wafer yields.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Mastercard is still tweaking their product. Remember, it's their product. There are other technology providers that work for Mastercard as well. And I think that they're getting there.
They're expecting to, we believe, launch the product in April in Florida. And we think that they're happy with it. And they've had a team of data scientists pouring over everything from the efficiencies to the restaurant to the customer experience. And when you're dealing with AI and voice recognition and things like that, they're going to tweak it and get it right because they're not going to put a product out in the market that they can't sell, and they're not 100% behind, and we think they're very close to getting there.
So we expect them to start a rollout in probably late April, early May.

    Prediction (one of UP, DOWN, SAME): UP